Ajanta Pharma Outlines Five Obesity Care Trends and Launches Ozanta®
MUMBAI, India, July 9, 2026 – In a PRNewswire‑distributed press release, Ajanta Pharma Limited highlighted five emerging trends that it expects will shape obesity and metabolic health management in India over the coming decade. The company noted that India hosts one of the world’s largest overweight and obese populations, a burden driving higher incidences of type‑2 diabetes, cardiovascular disease, fatty liver disease and other metabolic disorders.
The first trend identified is the growing recognition of obesity as a chronic disease influenced by genetics, physiology, environment, behaviour and lifestyle, prompting more structured, evidence‑based treatment pathways. The second trend foresees earlier intervention, shifting treatment initiation to before obesity‑related complications arise, with the aim of reducing long‑term health risks. The third trend emphasizes digital patient support, including remote consultations, medication reminders, lifestyle coaching and education tools, as essential for adherence and sustained outcomes. The fourth trend projects increased importance of personalized nutrition and lifestyle programmes that combine medical therapy with tailored dietary guidance, physical‑activity recommendations and behavioural support, requiring multidisciplinary collaboration among physicians, dietitians, fitness professionals and patient‑support teams. The fifth trend predicts a move from weight‑loss‑only conversations to integrated metabolic health, focusing on glycaemic control, cardiovascular risk reduction, quality of life and overall metabolic well‑being.
To align with these trends, Ajanta Pharma announced the expansion of its obesity management portfolio with Ozanta®, a semaglutide‑based therapy. Concurrently, the company is investing in patient‑awareness initiatives, healthcare‑professional engagement programmes, and digital platforms designed to improve treatment adherence and long‑term outcomes.
"The future of obesity management will be defined not only by scientific advancements but by how effectively we support patients throughout their journey. Building awareness, improving access to information, and strengthening patient engagement will be critical to long‑term success," said Mr. Pourus Vakil, President – India Business, Ajanta Pharma.
Ajanta Pharma described itself as a speciality pharmaceutical formulation company focused on branded generics across India, Asia and Africa, with a presence in more than 30 countries, including the United States and institutional business in Africa. The firm operates a state‑of‑the‑art R&D centre in Mumbai and runs seven world‑class manufacturing facilities in India. For further information, visit www.ajantapharma.com.